OPL-0301 is under clinical development by Valo Health and currently in Phase I for Left Ventricular Dysfunction. According to GlobalData, Phase I drugs for Left Ventricular Dysfunction have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OPL-0301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OPL-0301 is under development for the treatment of post-myocardial infarction (MI) participants with left ventricular dysfunction (LVD), atherosclerosis and acute kidney injury. It is administered through oral route. It acts by targeting sphingosine-1-phosphate (S1P). It is being developed based on opal platform.
Valo Health overview
Valo Health a technology company that is using human-centric data and machine learning-anchored computation to transform and accelerate the drug discovery and development process. It is headquartered in Boston, Massachusetts, the US.
For a complete picture of OPL-0301’s drug-specific PTSR and LoA scores, buy the report here.